Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001641172-25-021134
Filing Date
2025-07-28
Accepted
2025-07-28 12:43:48
Documents
16
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A form10-ka.htm   iXBRL 10-K/A 434290
2 EX-31.1 ex31-1.htm EX-31.1 3381
3 EX-31.2 ex31-2.htm EX-31.2 3236
4 EX-32.1 ex32-1.htm EX-32.1 3788
5 EX-32.2 ex32-2.htm EX-32.2 3819
  Complete submission text file 0001641172-25-021134.txt   706639

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE kapa-20241231.xsd EX-101.SCH 3026
7 XBRL LABEL FILE kapa-20241231_lab.xml EX-101.LAB 35430
8 XBRL PRESENTATION FILE kapa-20241231_pre.xml EX-101.PRE 23142
18 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 8235
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-42275 | Film No.: 251154559
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)